InnovAge Holding Corp. (INNV)
NASDAQ: INNVHealth CareMedical/Nursing ServicesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
INNV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.25B
- P/E (TTM)
- 152.67
- Forward P/E
- 18.32
- EPS (TTM)
- $0.06
- Dividend yield
- None
- 52-week range
- 4.70 – 12.64
- Day range
- 8.84 – 9.22
- Volume / Avg
- 498.36K / 595.71K
- Beta
- —
- Shares outstanding
- 136.46M
52-week range
INNV stock today
Shares of InnovAge (INNV) finished higher on Nov 20 at $9.16, a gain of 2.81% or $0.25 per share, versus the S&P 500's 3.70% decline. Shares are 27.5% below their 52-week high of $12.64, set on Jun 30, 2026 and 94.9% above the 52-week low of $4.70, in the middle of the past year's range. INNV is up 76.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 74.5%.
At 152.7x trailing earnings, InnovAge trades above the peer-group median of 29.7x. Its forward P/E of 18.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About InnovAge
Company profileInnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach.
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- CEO
- Mr. Patrick Blair
- Headquarters
- Denver, CO
- Employees
- 2,500
- IPO year
- 2021
- Website
- innovage.com
Financial highlights
Full financialsIn fiscal 2026, InnovAge generated $989.7 million in revenue, up 15.9% from fiscal 2025, its 3rd consecutive year of revenue growth. InnovAge reported a net loss of $2.5 million, compared with a loss of $30.3 million a year earlier. Gross margin was 23.0% (up from 18.0%) and operating margin 0.3%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $989.71M | $853.70M | $763.86M | $688.09M | $698.64M |
| Growth | +15.93% | +11.76% | +11.01% | -1.51% | +9.54% |
| Net income | $-2.54M | $-30.31M | $-21.34M | $-40.67M | $-6.52M |
| EPS (diluted) | $-0.02 | $-0.22 | $-0.16 | $-0.30 | $-0.05 |
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$12.00+31.00%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.14 vs $0.11
- Surprise
- +27.27%
INNV news
All INNV news- InnovAge Holding Corp. Resolves Civil Matter with U.S. Department of Justice & Participating StatesGlobeNewswire
- InnovAge expects $1.05B-$1.085B revenue and $105M-$115M adjusted EBITDA in fiscal 2027 as it reaffirms guidanceSeeking Alpha
- InnovAge Holding Corp. (INNV) Tops Q1 Earnings and Revenue EstimatesNasdaqINNV, NTRA
- InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2026GlobeNewswire
- InnovAge to Announce Fiscal First Quarter 2027 Financial Results and Host Conference Call Tuesday, November 3, 2026GlobeNewswire
- Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?NasdaqCAI, INNV
InnovAge peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PNTGThe Pennant Group Inc. | 34.64 | +1.61% | $1.22B | vs INNV |
| TDOCTeladoc Health Inc. | 7.45 | -4.36% | $1.36B | vs INNV |
| WGSGeneDx Holdings Corp. Class A | 45.46 | -7.68% | $1.36B | vs INNV |
| USPHU.S. Physical Therapy Inc. | 95.93 | +1.71% | $1.43B | vs INNV |
| AHCOAdaptHealth Corp. | 7.20 | -0.69% | $982.98M | vs INNV |
| OMDAOmada Health Inc. | 11.87 | -5.04% | $736.39M | vs INNV |
| SBCSBC Medical Group Holdings Incorporated | 5.17 | -7.68% | $530.32M | vs INNV |
| SRTAStrata Critical Medical Inc. Class A | 4.56 | -5.59% | $407.30M | vs INNV |
Indexes, lists and sector
InnovAge stock FAQ
What is InnovAge's stock price today?
INNV last traded at $9.16 as of Nov 20, 4:00 PM EST, up 2.81% on the day. Prices are delayed at least 15 minutes.
What is INNV's P/E ratio?
INNV trades at a trailing P/E ratio of 152.67 and a forward P/E of 18.32, compared with a median of 29.7 for its closest peers.
Who is InnovAge's CEO?
Mr. Patrick Blair is the chief executive officer of InnovAge Holding Corp., which has about 2,500 employees.
What is the INNV 52-week high?
The 52-week high for INNV is $12.64 and the 52-week low is $4.70. The stock is currently 27.5% below its high.